Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase (PARP) Inhibitors

Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels that refuel NQO1-dependent futile redox dru...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Cell
Hauptverfasser: Huang, Xiumei, Motea, Edward A., Moore, Zachary R., Yao, Jun, Dong, Ying, Chakrabarti, Gaurab, Kilgore, Jessica A., Silvers, Molly A., Patidar, Praveen L., Cholka, Agnieszka, Fattah, Farjana, Cha, Yoonjeong, Anderson, Glenda G., Kusko, Rebecca, Peyton, Michael, Yan, Jingsheng, Xie, Xian-Jin, Sarode, Venetia, Williams, Noelle S., Minna, John D., Beg, Muhammad, Gerber, David E., Bey, Erik A., Boothman, David A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2016
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161231/
https://ncbi.nlm.nih.gov/pubmed/27960087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.11.006
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge